A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Name: A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Published: 2023
License: Public Domain

Pfizer · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

multiple-myeloma

multiple myeloma, myeloma, relapsed multiple myeloma, refractory multiple myeloma, pf-06863135, bcma, bispecific, bispecific antibody, bcma-cd3 bispecific, elranatamab, magnetismm-3, external control arm

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 993916
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.